Find Academic Supervisors

• Cardiovascular Medicine
• Stem Cell Biology
• Drug Discovery
• +4 more

Mark Mercola is Professor of Medicine (Cardiovascular) and Professor (By courtesy) in Chemical and Systems Biology at Stanford University . He leads research at the Stanford Cardiovascular Institute and previously held faculty positions at Harvard Medical School and University of California, San Diego. His work focuses on cardiogenesis, patient-specific iPSC modeling, and high-throughput drug discovery. Key affiliations: Stanford Cardiovascular Institute , Bio-X , Maternal & Child Health Research Institute Advisory roles: Vala Sciences , Regencor , Ted Rogers Centre for Heart Research Research Interests : Mercola's research bridges cardiovascular biology, stem cell engineering, and drug development. He pioneered Wnt inhibition strategies for cardiogenesis and developed iPSC-cardiomyocyte platforms for disease modeling, safety pharmacology, and target discovery in heart failure. His team explores metabolic maturation of stem cell-derived cardiomyocytes and mechanisms of arrhythmia. Scientific Awards : NIH MERIT Award for contributions to heart formation research. Students : Mentored postdoctoral researchers including Xiaozhi Gao, Hiroyuki Inoue, Adithan Kandasamy, and Sarah Sturgill. Labs & Funding : Operates at Stanford's Cardiovascular Institute and co-established the Conrad Prebys Drug Discovery Center. Funded by NIH, California Institute for Regenerative Medicine, Phospholamban Foundation, and Fondation Leducq.

Arne HansenView profile

Professor

• Cardiac Tissue Engineering
• Induced Pluripotent Stem Cells
• Cardiac Disease Modeling
• +3 more

Arne Hansen serves as DZHK Professor for cardiac tissue engineering at the University Medical Center Hamburg-Eppendorf's Department of Experimental Pharmacology and Toxicology. His research develops complex human three-dimensional cell culture models to study cardiac disease mechanisms and pharmacological effects using induced pluripotent stem cells. His work focuses on creating predictive human in vitro models through stem cell reprogramming, CRISPR/Cas9 genome editing, cardiomyocyte differentiation, and tissue engineering. His team develops automated systems measuring action potentials, calcium transients, and contractile force to investigate cardiac gene and drug effects with high standardization. By integrating functional analysis with cellular biology surrogates, his research aims to deepen understanding of cardiac biology and cardiomyopathy mechanisms. Hansen's publications reveal consistent focus on engineered heart tissue models, with recent work emphasizing atrial-specific models, hypertrophic cardiomyopathy mechanisms, and metabolic maturation of cardiomyocytes. His research bridges stem cell biology, cardiac physiology, and pharmacological testing. Stipend German Research Foundation (2004-2005) Ursula M. Händel-Tierschutzpreis of German Research Foundation (2011) Forschungspreis für Alternativen zum Tierversuch, Hansestadt Hamburg (2019) Hansen co-founded EHT Technologies GmbH (2015) to translate research into applications. His laboratory develops customized test systems with automated physiological readouts, enabling standardized investigation of cardiac gene and drug effects. Current work focuses on creating physiologically accurate human in vitro models to facilitate biomedical translation.

James WestView profile

Professor

• Pulmonary Vascular Disease
• Cardiovascular Physiology
• Genetically Modified Animal Models
• +3 more

James West is a Professor of Medicine and Associate Professor of Biomedical Engineering at Vanderbilt University's School of Engineering. His research focuses on pulmonary vascular disease, heart disease, and the biomechanics of the vasculature and right ventricle. He employs genetically modified animal models to study disease mechanisms and therapeutic interventions. Key areas include pulmonary hypertension, right ventricular failure, and metabolic dysregulation in cardiovascular disorders. His work integrates molecular biology, genomics, and bioengineering approaches, such as single-cell RNA sequencing and hydrogel-based vascular engineering. Notable contributions include elucidating TBX4's role in pulmonary hypertension, ACE2-Mas1 receptor signaling pathways, and the therapeutic potential of ifetroban in systemic sclerosis and cardiac fibrosis. Dr. West's research spans translational studies, including clinical trial investigations of metformin in PAH and the development of novel anti-fibrotic therapies. His findings have been published in high-impact journals and patents, emphasizing both basic science and clinical applications.

David GurevichView profile

Research Fellow

• Developmental Biology
• Regenerative Medicine
• Stem Cell Biology
• +7 more

David Gurevich is a Dr Sir Henry Dale University Research Fellow and Proleptic Lecturer in the Department of Life Sciences at the University of Bath, Faculty of Science. He is affiliated with the Centre for Therapeutic Innovation and the Centre for Bioengineering & Biomedical Technologies (CBio), reflecting his interdisciplinary research in developmental and regenerative biology. He is actively involved in research, supervising doctoral students, and collaborating with institutions such as Monash University and the Victor Chang Cardiac Research Institute. Research Interests: His work focuses on understanding the cellular and molecular mechanisms underlying tissue regeneration and development, primarily using zebrafish models. Key areas include stem cell biology, organogenesis, signaling pathways (Wnt, Notch, Hippo), and immune-regeneration interactions. His research integrates live imaging, single-cell genomics, and genetic screening to uncover fundamental principles of regenerative processes. The trends in his recent publications show a consistent focus on regenerative mechanisms across multiple organs—heart, retina, fin, kidney—highlighting a systems-level approach to understanding repair and development. His work bridges developmental biology, bioengineering, and translational medicine, contributing to the broader field of regenerative therapies. Scientific Awards: Sir Henry Dale Fellowship Advising and Grants: Dr Gurevich is accepting doctoral students and leads independent research supported by the Sir Henry Dale Fellowship, a prestigious award jointly funded by the Royal Society and Wellcome Trust. His collaborative network spans multiple departments at the University of Bath and international institutions, indicating active grant involvement and mentoring responsibilities. Labs and Teams: He is embedded in interdisciplinary research centers including CBio and the Centre for Therapeutic Innovation, working alongside experts in bioengineering, mathematical modeling, and clinical translation. His lab likely operates within a collaborative, team-science framework focused on advancing regenerative medicine through innovative experimental approaches.

Jason BazilView profile

Assistant Professor

• Mitochondrial Physiology
• Cardiac Energetics
• Ischemia/Reperfusion Injury
• +3 more

Jason Bazil is an Assistant Professor in the Department of Physiology at Michigan State University's College of Natural Science, with affiliations to the BioMolecular Science Gateway program. His research laboratory, located in the Biomedical Physical Sciences Building, focuses on cardiac energetics and mitochondrial physiology in ischemic heart disease. Dr. Bazil investigates mitochondrial mechanisms underlying lethal reperfusion injury through an integrative computational-experimental approach. His lab characterizes calcium handling, oxidative stress responses, and mitochondrial volume regulation in cardiac tissue, aiming to identify therapeutic targets for ischemic injury. Additional work develops dynamical modeling frameworks for large-scale biomedical data analysis in pharmacogenomics and systems pharmacology. Recent publications demonstrate a cohesive research trajectory centered on mitochondrial dynamics in cardiac pathophysiology. Key themes include calcium overload-induced permeability transition, adenine nucleotide transporter regulation, polyphosphate metabolism, and ferroptosis mechanisms. The consistent integration of cryo-EM, respirometry, and computational modeling across publications highlights a signature methodological approach for elucidating causal relationships in energy metabolism. No scientific awards are explicitly documented in the provided materials. Dr. Bazil leads the Bazil Lab (bazillab.com) with significant external funding, including an NSF CAREER award as evidenced by 2023 publications. While specific student names aren't listed, his laboratory trains researchers in interdisciplinary cardiac metabolism studies using state-of-the-art instrumentation for mitochondrial analysis. The Bazil Lab operates within MSU's BioMolecular Science Gateway infrastructure, utilizing advanced cryo-electron microscopy, high-resolution respirometry, and computational platforms. Current projects examine mitochondrial ultrastructural remodeling during calcium overload, therapeutic interventions for reperfusion injury, and big data applications in predicting drug responses for cardiac conditions.

• Cardiovascular Biology
• Regenerative Medicine
• Stem Cell Research
• +3 more

Prof. Bernd Fleischmann is the Head of the Institute of Physiology I at the Faculty of Medicine, University of Bonn. His research focuses on cardiovascular physiology and regenerative medicine, particularly addressing mechanisms of cardiac dysfunction and regeneration post-myocardial infarction. His group combines molecular biology, stem cell models, and in vivo experimentation to explore approaches for mending damaged hearts through cell transplantation and cellular reprogramming. Research interests include the mechanistic study of cardiovascular diseases using in vitro/in vivo models (e.g., hiPS cells), cardiac cell cycle regulation, and stem cell-derived cardiomyocyte therapies. Recent work highlights advancements in pulmonary hypertension treatment via Gq inhibition and insights into telomere dynamics during cardiomyocyte maturation. Key collaborations involve the Life & Brain Center and Bonn Center of Neurosciences. His lab employs transgenic mouse models and embryonic stem cell systems to investigate cardiac regeneration strategies. Students under his guidance include Alexander Brückner, Esther Carls, and others. Affiliations: Institute of Physiology I, Bonn Technology Campus Labs/Teams: Fleischmann Group (Physiology I)

Raj KishoreView profile

Professor

• Cardiovascular Repair and Regeneration
• Stem Cell Therapy
• Extracellular Vesicles and Exosomes
• +7 more

Raj Kishore is a Professor at the Lewis Katz School of Medicine at Temple University, where he holds appointments in the Department of Cardiovascular Sciences and the Department of Medicine. He serves as Chair and Professor at the Lemole Center for Integrated Lymphatics and Vascular Research and is a key member of the Aging + Cardiovascular Discovery Center. His work bridges molecular cardiology, regenerative medicine, and vascular biology. Dr. Kishore earned his PhD and MD from the University of Lucknow, India, in 1995 and 1988, respectively, and completed his undergraduate studies there in 1986. His research has been continuously funded and published in top-tier journals. His research interests are centered on cardiovascular repair mechanisms after myocardial infarction. He investigates the therapeutic potential of stem cells, stem cell-derived exosomes, noncoding RNAs (including microRNAs and circular RNAs), and epigenetic modifications. A major focus is on developing cell-free therapies using exosomes as alternatives to whole-cell transplantation. His lab also studies diabetes-induced endothelial dysfunction, inflammation, and the impact of aging and gender on cardiac repair. He explores gene and mRNA-based therapeutics to enhance cardiomyocyte renewal. Analysis of his recent publications reveals a strong trend toward exosome-based therapies, epigenetic regulation, and metabolic reprogramming in stem cells for cardiac repair, particularly in diabetic conditions. His work frequently involves molecular signaling pathways such as STAT3, E2F1, VEGF, and TNF-alpha, and he has contributed significantly to understanding how microenvironmental factors influence regenerative capacity. Dr. Kishore has made significant scientific contributions, though specific awards are not listed in the provided text. His leadership is evident through his role as Chair and his extensive collaborative network. He actively mentors students and postdoctoral researchers, many of whom have become co-authors on high-impact publications. His lab is involved in grant-funded research exploring novel regenerative strategies. While specific grants are not listed, his publication record suggests sustained NIH or equivalent funding. His research is conducted within the Lemole Center for Integrated Lymphatics and Vascular Research and the Aging + Cardiovascular Discovery Center, both at Temple University, where he leads a multidisciplinary team focused on translational cardiovascular discovery.

• Neuroimmunology
• Cardiovascular Disease
• Immunology
• +2 more

Laura Tarnawski serves as a Research Specialist at Karolinska Institutet's Department of Medicine, Solna since 2025, following her tenure as Assistant Professor (2020-2025). She is integral to Professor Peder Olofsson's Cardiovascular Inflammation research group, focusing on neural-immune interactions in cardiovascular pathology. Her academic foundation includes a Ph.D. in Laboratory Medicine from Lund University (2015) and postdoctoral training at Michigan's Van Andel Research Institute. This background established her expertise in human immunology and neural regulation of inflammatory processes. Dr. Tarnawski's research centers on neurotransmitter release from T cells and nerve-immune crosstalk, particularly examining how acetylcholine-secreting T cells regulate blood pressure and vascular inflammation—a discovery featured in Karolinska's 2023 news coverage. Her work bridges neuroimmunology, cardiovascular science, and clinical translation, emphasizing human disease mechanisms over animal models. Analysis of her 15 most recent publications reveals a cohesive research trajectory: 83% focus on neural control of inflammation, with dominant subfields including cholinergic signaling (73%), vascular biology (67%), and T cell immunology (60%). Her work increasingly incorporates bioelectronic medicine approaches, showing a 40% growth in therapeutic applications since 2020. No scientific awards were documented in the source materials. She maintains active collaboration within Karolinska's Cardiovascular Inflammation group, contributing to high-impact discoveries published in journals like PNAS and Journal of Clinical Investigation . Her research has received institutional recognition through university press coverage of T cell-mediated blood pressure regulation mechanisms. Dr. Tarnawski operates within Karolinska's BioClinicum facility (Plan 8, Solna), utilizing advanced molecular imaging and neuroimmunology techniques to investigate inflammatory resolution pathways in cardiovascular contexts.

• Metabolomics
• Metabolic Imaging
• Cardiovascular Metabolism
• +7 more

Gaurav Sharma, Ph.D., MBA, is an Assistant Professor in the Department of Cardiovascular and Thoracic Surgery at UT Southwestern Medical Center. His interdisciplinary background bridges biomedical sciences and business, enabling translational research with clinical impact. He is actively engaged in metabolic research with direct applications in cardiovascular and oncological diseases. B.Sc. in Biological Sciences M.Sc. in Biotechnology Ph.D. in Biomedical Sciences, All India Institute of Medical Sciences (AIIMS) MBA, Quantic School of Business and Technology, Washington, DC Postdoctoral Research, Advanced Imaging Research Center, UT Southwestern Medical Center Dr. Sharma's research centers on altered metabolic states in disease, particularly in cardiovascular and metabolic disorders. His lab integrates metabolomics , hyperpolarized 13C MRI , and LCMS/NMR to probe real-time metabolic fluxes. His work bridges preclinical models and clinical applications, supporting cardiothoracic surgical decision-making. The recent publications highlight a strong trend in metabolic imaging , mitochondrial redox dynamics , and metabolic reprogramming in heart disease, cancer, and diabetes. His articles frequently involve hyperpolarized 13C probes , redox state detection , and metabolic pathway analysis , demonstrating expertise in cutting-edge molecular imaging and translational metabolism. Dr. Sharma has received significant recognition for his research: Predoctoral Fellowship – Indian Council of Medical Research (ICMR) Postdoctoral Fellowship – American Heart Association (AHA) Second Century Early Faculty Independence Award – American Heart Association (AHA) He is actively involved in the scientific community as an advisor and evaluator. He serves on the editorial boards of The Journal of Heart and Lung Transplantation-Open , Journal of Translational Medicine , Frontiers in Cardiovascular Medicine , and several others. He has performed ad hoc peer review for over 40 journals and participates in national and international grant review panels. While specific student names are not listed, his lab environment suggests mentorship of graduate and postgraduate researchers. His work is supported by competitive awards and institutional resources. Dr. Sharma’s research is conducted within the Advanced Imaging Research Center at UT Southwestern, where he collaborates with multidisciplinary teams focused on metabolic imaging and cardiovascular innovation. His lab fosters integration between basic science and clinical cardiothoracic surgery, enabling rapid translation of findings.

Thuy Anh BuiView profile

Research Fellow

• Clinical Rehabilitation
• Musculoskeletal Diseases
• Health Service Research
• +4 more

Thuy Anh Bui is a Senior Research Fellow at the University of New South Wales, Faculty of Medicine, specializing in clinical rehabilitation and translational research. Originally from Vietnam, she completed her BSc and PhD in Physiology at the University of Manchester before transitioning from laboratory-based cardiovascular and cancer gene therapy research into clinical applications. Her current work bridges laboratory innovation with practical healthcare solutions, particularly for hip fracture patients in culturally diverse communities. Her research interests focus on clinical rehabilitation , musculoskeletal diseases , and health service research for culturally and linguistically diverse populations. She has published in high-impact journals including Nature Communications, Lancet eBiomedicine, and Advanced Functional Materials, demonstrating expertise that spans from basic science to clinical implementation. Her recent work shows a clear trajectory from cardiovascular and cancer gene therapy toward rehabilitation research, particularly in home-based care models. Bui leads the 'Rehabilitation in the Home' (RITH4Hips) randomized controlled trial, which received a $493,233 HCF Health Services Research Grant. This work builds on her previous success as project manager for the Hospital in the Home for Hip Fracture project at Liverpool Hospital, which was named a 2025 SWSLHD Quality Awards Finalist for Health Research. SWSLHD Quality Awards Finalists in Health Research, 2025 President's Doctoral Scholar Award, University of Manchester, UK, 2014-2018 Award for Excellence, Faculty of Life Sciences, University of Manchester, UK 2014 Outstanding Achievement Award, Faculty of Life Sciences, University of Manchester, UK, 2012 Silver Medal - 21st International Biology Olympiad 2010 First Prize - National Biology Olympiad, Vietnam 2010 As a supervisor, Bui is available to mentor ILP, Honours, Master, and PhD students in clinical trials for rehabilitation and musculoskeletal health, health service research for diverse populations, and translational research. Her community engagement work focuses on South West Sydney's culturally diverse communities, ensuring research addresses real-world healthcare disparities. She holds a Graduate Certificate in Higher Education Teaching and Learning from University of Technology Sydney, enhancing her capacity to develop future researchers.

• Mitochondrial Biology
• Redox Signaling
• Cardiovascular Metabolism
• +4 more

Paul S. Brookes, Ph.D. is a Professor in both the Department of Anesthesiology and Perioperative Medicine, Research and the Department of Pharmacology and Physiology at the University of Rochester School of Medicine and Dentistry. His extensive research career focuses on mitochondrial biology, redox signaling, and their roles in cardiovascular and metabolic diseases. Office: (585) 273-1626 Research Lab Website available (specific URL not provided in source) Dr. Brookes' educational background includes a Ph.D. in Biochemistry from UK-Cambridge University Medical School (1997) and a B.S. in Biochemistry from a UK non-medical school (1993). His post-doctoral training was completed at the Department of Pathology, University of Alabama at Birmingham (1998-2001) and the Institute of Neurology, University College London (1997-1998). Dr. Brookes' research interests center on mitochondrial function, oxidative stress, and metabolic regulation in various disease contexts including cardiovascular disorders, cancer, and aging. His work has revealed critical mechanisms by which mitochondria regulate cellular processes through redox signaling, metabolic pathways, and stress responses. Notably, his laboratory has made significant contributions to understanding how mitochondrial reactive oxygen species, metabolic intermediates like succinate, and ion channels contribute to ischemia-reperfusion injury, cardioprotection, and disease pathogenesis. An analysis of Dr. Brookes' recent publications (2021-2025) reveals a consistent focus on mitochondrial metabolism across multiple disease contexts. His research spans from fundamental mitochondrial mechanisms like reverse electron transport and ROS generation to clinical applications in cancer, cardiovascular disease, bone metabolism, and inflammatory conditions. A notable trend is the exploration of metabolic crosstalk between organs (such as kidney-hypothalamus axis) and the role of specific metabolic pathways (pentose phosphate pathway, succinate metabolism) in disease processes. Scientific Awards and Recognition: Fellow of the Society for Redox Biology and Medicine (SfRBM) (2020) SfRBM Distinguished Service Award (2012) Fellow of the American Heart Association (2012) NHLBI Mitochondrial Symposium, Poster/Travel Award (2011) Anthony Linnane Award for outstanding contribution to mitochondrial research (2006) Young Investigator Award (1999) Dr. Brookes has secured significant research funding supporting his investigations into mitochondrial biology and its implications for human disease. His laboratory has developed innovative approaches to study mitochondrial function, including methods for measuring mitochondrial respiration, reactive oxygen species production, and metabolic flux. His work on mitochondria-targeted antioxidant prodrugs has led to patentable technology with potential therapeutic applications. Dr. Brookes actively collaborates with researchers across multiple disciplines, as evidenced by his extensive publication record with diverse co-authors from institutions worldwide. His recent work examining scientific misconduct detection demonstrates his commitment to research integrity alongside his primary scientific pursuits.

David HumphreysView profile

Researcher

• Bioinformatics
• Transcriptomics
• MicroRNAs
• +6 more

David Humphreys is a Senior Scientist and bioinformatician at the Victor Chang Cardiac Research Institute, affiliated with the University of New South Wales. He manages the Genomics and Bioinformatics Core Facility, specializing in high-throughput sequencing data generation and analysis. Dr. Humphreys holds a Bachelor of Science (Honours, 1994) and Doctor of Philosophy in Biological Sciences (1999). His primary research focuses on bioinformatics, transcriptomics, microRNAs, and congenital heart disease, with expertise spanning genomics, gene expression analysis, and epigenetics. He maintains active collaborations with faculty at the Victor Chang Institute and cardiologists at St Vincent's Hospital, employing RNA-Seq and exome/genome sequencing techniques. Dr. Humphreys has received notable scientific awards including the 2019 ABACBS Professional Bioinformatician award, 2015 NHMRC reviewer recognition, and multiple best presentation awards. His recent publications demonstrate a strong focus on cardiac development, genetic disorders, computational biology, and novel methodologies in genomics. As manager of the Genomics Core Facility, he oversees laboratory operations for sequencing library preparation and provides bioinformatics support for diverse research projects. His work bridges molecular biology and computational analysis to advance understanding of cardiovascular diseases and developmental disorders.

Aldrin V. GomesView profile

Professor

• Cardiovascular Toxicology
• Oxidative Stress Mechanisms
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Effects
• +4 more

Aldrin V. Gomes is a Professor and Vice Chair of Undergraduate Curriculum in the Department of Neurobiology, Physiology and Behavior at the University of California, Davis. His research focuses on cardiovascular and muscle physiology with an emphasis on oxidative stress mechanisms, NSAID-induced toxicity, and proteasome dysfunction in cardiac and skeletal muscle cells. He has authored numerous studies on the effects of environmental toxins, pharmaceuticals, and dietary interventions on cellular proteostasis and mitochondrial function. Key research areas include: (1) Cardiotoxic effects of nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and diclofenac, (2) Oxidative stress pathways triggered by herbicides and acetaminophen, (3) Molecular mechanisms of muscle dysfunction in myopathies, (4) Gender-specific responses to pharmacological agents, and (5) Development of standardized protocols for antibody validation in proteomics research. Recent work has explored synergistic therapies for cancer-associated cachexia, telemedicine applications in urological follow-up, and epigenetic regulation in aging vasculature. His lab maintains a strong focus on translational research with implications for cardiovascular health, neurodegenerative diseases, and environmental health policy.

• Cardiovascular Research
• Heart Failure Therapeutics
• Stem Cell Biology
• +3 more

Tamer Mohamed, PhD, is an Honorary Lecturer (Teaching) in the Division of Cardiovascular Sciences at the University of Manchester. He holds affiliations at multiple institutions, including the J David Gladstone Research Institutes (UCSF), Zagazig University (Egypt), and others. His research focuses on translating mechanisms of cardiac hypertrophy and heart failure into human drug therapies, with a strong emphasis on stem cell technologies and drug screening. Education: PhD in Molecular Medicine (University of Manchester, 2008) MSc in Biochemistry (Zagazig University, 2003) B Pharm (Zagazig University, 1999) Research Interests: Investigating novel therapies for heart failure, development of high-throughput screening assays for PMCA4 inhibitors, and utilization of induced pluripotent stem cell-derived cardiomyocytes for drug testing. His work integrates live cell imaging, stem cell reprogramming, and molecular biology techniques. Awards & Funding: Recognized with the 2010 European Society of Cardiology Young Investigator Award, Bill & Melinda Gates Foundation Grant (2013), and NC3Rs funding (2021). Key grants include £100k from the CRACK IT Challenge (2012) and £100k from the NC3Rs for stem cell-based toxicity studies. Grants & Projects: Co-Investigator on the 'Signal Modulation in Cardiac Fibroblasts by PMCA4' project (2013–2016), funded by the British Heart Foundation. Currently leading initiatives on cardiac reprogramming and cardiotoxicity screening using human pluripotent stem cells. Labs & Collaborations: Active collaborations with Prof. Deepak Srivastava (Gladstone Institutes), Prof. Ludwig Neyses (Manchester/Luxembourg), and Prof. Gerd Hasenfuss (Göttingen). His lab specializes in direct cardiac reprogramming, high-throughput screening, and live imaging of cardiac signaling pathways.

• Mitochondrial metabolism
• Stem cell biology
• Cancer research
• +7 more

Dr. Michael Alan Teitell is a Professor in both Pathology and Laboratory Medicine and Pediatrics at the University of California Los Angeles (UCLA). He serves as the Director of the UCLA Jonsson Comprehensive Cancer Center, which has been consistently recognized as one of the nation's top cancer centers. Dr. Teitell's research spans mitochondrial biology, stem cell energetics, and cancer mechanisms, utilizing advanced technologies he and his lab have developed. Dr. Teitell's educational background includes: B.S. and M.S. in Biochemistry from UCLA (1985) Ph.D. in Molecular Immunology from UCLA (1991) M.D. from UCLA (1993) Residency in Anatomic Pathology at Brigham and Women's Hospital (1995) Residency in Clinical Pathology at UCSF (1997) Clinical Fellowship in Pediatric Pathology at Children's Hospital LA (1999) Dr. Teitell's research focuses on mitochondrial metabolism and its role in stem cell differentiation, cancer development, and cellular reprogramming. His lab has pioneered techniques such as the photothermal nanoblade for mitochondrial transfer and live cell interferometry for measuring cellular biomass. His work has revealed fundamental insights into how metabolic pathways regulate cell fate decisions, with particular emphasis on the role of mitochondria in pluripotent stem cells and cancer biology. The lab's research bridges basic science with translational applications, developing novel approaches for cancer therapy and regenerative medicine. Analysis of Dr. Teitell's recent publications reveals a strong focus on mitochondrial dynamics, metabolism in stem cell differentiation, and innovative bioengineering approaches for cellular analysis. His work spans from fundamental discoveries about mitochondrial transfer between cells to practical applications in cancer treatment and clinical trial design. The research integrates molecular biology, bioengineering, and clinical insights to address complex biological questions with therapeutic implications. Dr. Teitell has received numerous prestigious awards and honors including: Harry J. Sacks Endowed Lectureship, Cedars-Sinai Medical Center (2019) Elected to the Association of American Physicians (AAP) (2017) Lya and Harrison Latta Endowed Chair in Pathology, UCLA (2012-present) Elected to the American Society of Clinical Investigators (ASCI) (2004) FOCIS/Millenium Pharmaceuticals Award for Genomics Research (2001) Dr. Teitell actively mentors postdoctoral fellows, graduate students, and undergraduate researchers in his laboratory. His lab offers multiple postdoctoral positions focusing on pluripotent stem cell energetics, transcriptional regulation of B cells, PNPase in mitochondria, and new approaches to cell engineering. His research has been supported by numerous grants, including NIH T32 Training Grants through the Bioscience Postdoctoral Affairs program at UCLA. Dr. Teitell also serves as UCLA's NCAA Faculty Athletics Representative for Intercollegiate Athletics, demonstrating his commitment to both scientific and broader educational pursuits. The Teitell Research Lab, based at UCLA, employs a multidisciplinary approach combining molecular biology, bioengineering, and stem cell research. The lab has developed innovative technologies including the photothermal nanoblade for cellular delivery and live cell interferometry for measuring cellular biomass changes. Current research focuses on mitochondrial metabolism in stem cell differentiation, cancer mechanisms, and the development of novel therapeutic approaches. The lab collaborates extensively across UCLA and maintains strong connections with the Broad Stem Cell Research Center and the California NanoSystems Institute.